Anita D'Souza, MD

Associate Chief, Research, Division of Hematology/Oncology; Professor of Medicine

view physician profile

Locations

Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Anita D’Souza, MD, MS completed medical school in Goa Medical College, India where she graduated at the top of her class and was voted Best Medical Graduate. She completed her Hematology and Medical Oncology fellowship at the Mayo Clinic, Minnesota.

Research Interests

Dr. D'Souza's clinical and research work is focused on plasma cell cancers (e.g. multiple myeloma, AL amyloidosis, POEMS syndrome, Waldenstrom Macroglobulinemia) and the use of hematopoietic cell transplantation to treat these diseases. She serves as a scientific director of the Plasma Cell Disorders and Adult Solid Tumors working committee in the Center for International Blood and Marrow Transplant Research (CIBMTR). She is principal investigator on clinical trials in amyloidosis and multiple myeloma. She is a recipient of the 2016 KL2 Career Development Award from the Clinical and Translational Science Institute. Dr. D’Souza is board certified in Internal Medicine, Hematology and Medical Oncology.

Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis.

(D'Souza A, Szabo A, Akinola I, Finkel M, Flynn KE.) Eur J Haematol. 2024 Jun;112(6):900-909 PMID: 38350661 PMCID: PMC11271248 SCOPUS ID: 2-s2.0-85185450309 02/14/2024
Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients.

(Shaw BE, Flynn KE, He N, Cusatis R, D'Souza A, Hamilton BK, Horowitz MM, Mattila D, Phelan R, Lee SJ, Brazauskas R.) Cancer. 2024 May 15;130(10):1826-1835 PMID: 38198511 PMCID: PMC11058023 SCOPUS ID: 2-s2.0-85181878144 01/10/2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.

(Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C.) Bone Marrow Transplant. 2024 May;59(5):647-652 PMID: 38361116 SCOPUS ID: 2-s2.0-85185115608 02/16/2024
Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.

(Brazauskas R, Flynn K, Krishnan A, Landau H, Giralt S, Pasquini MC, Stadtmauer EA, D'Souza A.) Br J Haematol. 2024 Apr;204(4):1429-1438 PMID: 38348544 PMCID: PMC11006567 SCOPUS ID: 2-s2.0-85185482209 02/13/2024
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.

(Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C.) Blood Cancer J. 2024 Mar 06;14(1):38 PMID: 38443358 PMCID: PMC10915134 SCOPUS ID: 2-s2.0-85186929795 03/06/2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

(Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R.) Blood Cancer J. 2024 Mar 05;14(1):35 PMID: 38443345 PMCID: PMC10914756 SCOPUS ID: 2-s2.0-85186867281 03/06/2024
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.

(Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan M.) Blood Cancer J. 2024 Mar 05;14(1):36 PMID: 38443341 PMCID: PMC10914796 SCOPUS ID: 2-s2.0-85186936720 03/06/2024
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.

(Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M.) Bone Marrow Transplant. 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.

(Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M.) Transplant Cell Ther. 2024 Mar;30(3):285-297 PMID: 38142942 SCOPUS ID: 2-s2.0-85183537164 12/25/2023
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.

(Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B.) Br J Haematol. 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023
Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis.

(D'Souza A, Singh A, Szabo A, Lian Q, Pezzin L, Sparapani R.) Res Sq. 2024 Jan 03 PMID: 38260686 PMCID: PMC10802702 01/23/2024
Amyloid consults do not have to be vexing.

(D'Souza A.) Hematology Am Soc Hematol Educ Program. 2023 Dec 08;2023(1):407-412 PMID: 38066929 PMCID: PMC10727086 12/09/2023